The Immune checkpoint blockers (ICB) have greatly improved clinical outcomes in multiple
cancer types and are increasingly being used in earlier disease settings alone or
in combination with other therapies. However, rare but life-threatening complications
defined as immune-related adverse events (irAE) as ICI-induced myocarditis can occur,
justifying close monitoring and specific management [
[1]
,
[2]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.Lancet. 2018; 391: 933
- Myocarditis with immune checkpoint blockade.N Engl J Med. 2017; 376: 292
- Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque.Circulation. 2020; 142: 2299-2311
- 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European Society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology Society (IC-OS) -.Eur Heart J. 2022 Aug 26; ehac244
- Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review.JAMA Cardiol. 2021; 6: 1329-1337
- Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology.Circulation. 2019; 140: 80-91
- Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.Eur Heart J. 2022; 43: 280-299
- Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: report from an international registry.Eur J Cancer. 2022; S0959–8049: 443-449
Palassin P, Faillie JL, Coustal C, Quantin X, Topart D, Roubille F, et al. Under-reporting of major cardiac adverse events with immune checkpoint inhibitors in clinical trials: importance of post-marketing pharmacovigilance surveys. J Clin Oncol. Accepted for publication Sept 2022.
- Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations.J Am Coll Cardiol. 18 déc 2018; 72: 3158-3176
- 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Eur Heart J. 2021 Apr 7; 42: 1289-1367
- Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.Ann Rheum Dis. 2022; 81: e32
Article info
Publication history
Published online: October 28, 2022
Accepted:
September 24,
2022
Received:
September 5,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.